Update on the management of relapsed/refractory chronic lymphocytic leukemia
- Author(s)
- Bennett, R; Seymour, JF;
- Details
- Publication Year 2024-02-21,Volume 14,Issue #1,Page 33
- Journal Title
- Blood Cancer Journal
- Publication Type
- Review
- Abstract
- Chronic lymphocytic leukemia (CLL) predominantly affects older adults, characterized by a relapsing and remitting pattern with sequential treatments available for many patients. Identification of progressive/relapsed CLL should prompt close monitoring and early discussion about the next therapies when treatment indications are present. The intervening period represents an opportunity to optimize patient health, including establishing adequate vaccination and surveillance for second primary malignancies, and treating non-CLL-related comorbidities which may impact well-being and CLL therapy. We now see patients with relapsed/refractory (RR) CLL in the clinic who have been previously treated with chemoimmunotherapy (CIT) and/or one or more novel therapies. Continuous covalent inhibitors of Bruton's tyrosine kinase (cBTKi) and fixed-duration venetoclax (Ven)-anti-CD20 monoclonal antibody (mAb) are preferred over CIT given the survival advantages associated with these therapies, although have never been evaluated head-to-head. While both classes are effective for RR CLL, potential side effects and the logistics of administration differ. Few randomized data demonstrate the sequential use of cBTKi and fixed-duration Ven-anti-CD20 mAb; however, they may be used in either sequence. Newer non-covalent BTKi, active against BTK C481 resistance mutations emerging with continuous cBTKi exposure, and novel approaches such as BTK degraders, bispecific antibodies, and chimeric antigen receptor T-cell therapies demonstrate impressive efficacy. In this review of RR CLL we explore relevant investigations, consideration of broader CLL- and non-CLL-related health needs, and evidence for efficacy and safety of B-cell receptor inhibitors and Ven, including available data to support drug sequencing or switching. We describe novel approaches to RR CLL, including rechallenging with fixed-duration therapies, allogeneic stem cell transplant indications in the novel therapy era, and highlight early data supporting the use of T-cell directing therapies and novel drug targets.
- Publisher
- Springer Nature
- Keywords
- Humans; Aged; *Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy/etiology; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; *Lymphoma, B-Cell/drug therapy; *Antineoplastic Agents/therapeutic use; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal/therapeutic use
- Department(s)
- Clinical Haematology
- Publisher's Version
- https://doi.org/10.1038/s41408-024-01001-1
- Open Access at Publisher's Site
https://doi.org/10.1038/s41408-024-01001-1- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-03-28 06:48:08
Last Modified: 2024-03-28 06:51:46